9 completed, 5 recruiting, 3 active not recruiting, 2 terminated. 21 Phase 1, 11 Phase 2.
Follow Mercaptopurine: new trials by email Literature Review of Mercaptopurine trials Research Report on Mercaptopurine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients Hydroxyurea, Hydroxycarbamide, Valproic acid, 6-Mercaptopurine (6-MP) - Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult | Phase 1 / Phase 2 | Recruiting | Haukeland University Hospital | 48 | 2024-05-23 | 2025-06-29 |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Dexamethasone, Mitoxantrone, PEG asparaginase - Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Tanja Andrea Gruber | 90 | 2023-11-03 | 2026-06-03 |
| Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Atezolizumab, 6-mercaptopurine, 6-thioguanine - Solid Tumor, Adult, Metastatic Cancer | Phase 1 / Phase 2 | Completed | Kristoffer Rohrberg | 18 | 2022-09-01 | 2026-01-14 |
| Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax Venetoclax, Navitoclax, Dexamethasone - Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 35 | 2022-08-25 | 2026-10-15 |
| Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia Venetoclax, 6-mercaptopurine - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Recruiting | University Hospital, Antwerp | 10 | 2022-07-15 | 2022-08-18 |
| Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma 6-mercaptopurine - Glioblastoma, Cancer | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 27 | 2022-07-01 | 2024-02-28 |
| Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride - B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 24 | 2022-03-17 | 2026-05-28 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Ruxolitinib, Cyclophosphamide, Cytarabine - Acute Lymphoblastic Leukemia, ALL, Childhood | Phase 1 | Recruiting | University of Chicago | 15 | 2019-05-28 | 2026-06-29 |
| Thiopurine EnhAnced Maintenance Therapy Thioguanine (oral) - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Completed | Kjeld Schmiegelow | 30 | 2016-10-01 | 2020-04-15 |
| Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I ITMHA, Dexamethasone, Mitoxantrone - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 50 | 2016-01-29 | 2026-06-24 |
| Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia Carfilzomib, Dexamethasone, Mitoxantrone - Acute Lymphoblastic Leukemia (ALL) | Phase 1 | Completed | Amgen | 141 | 2015-02-16 | 2025-06-04 |
| Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults MLN 9708, Vincristine, Cytarabine - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 1 | Completed | Massachusetts General Hospital | 19 | 2014-12-01 | 2019-11-26 |
| Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions Mercaptopurine 20mg/ml oral suspension, Mercaptopurine 50mg tablet - Acute Lymphoblastic Leukemia | Phase 1 | Completed | Nova Laboratories Limited | 70 | 2012-09-01 | 2013-12-02 |
| Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 276 | 2011-08-26 | 2026-07-15 |
| Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease Delayed Release 6 mercaptopurine, 6 Mercaptopurine - Crohn's Disease | Phase 1 / Phase 2 | Terminated | Teva GTC | 70 | 2010-11-01 | 2013-03-07 |
| Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride - Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | Children's Oncology Group | 104 | 2009-02-23 | 2021-04-27 |
| Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients Delayed Release 6 mercaptopurine, 6 Mercaptopurine - Crohns Disease | Phase 1 | Completed | Teva GTC | 12 | 2008-12-01 | 2009-07-17 |
| Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg Mercaptopurine 50 mg, Purinethol® Tablets 50 mg - Healthy | Phase 1 | Completed | Mylan Pharmaceuticals Inc | 60 | 2003-11-01 | 2024-04-24 |
Showing 20 of 21. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Burkitt Lymphoma (4) · Crohn Disease (2) · Leukemia, Myeloid, Acute (2) · Neoplasms (2) · Carcinoma, Renal Cell (1) · Glioblastoma (1) · Hereditary leiomyomatosis and renal cell cancer (1) · Leukemia, Biphenotypic, Acute (1) · Myelodysplastic Syndromes (1) · Myofibroma (1) · Neoplasm Metastasis (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
M.D. Anderson Cancer Center (2) · St. Jude Children's Research Hospital (2) · Teva GTC (2) · Amgen (1) · Children's Oncology Group (1) · City of Hope Medical Center (1) · Haukeland University Hospital (1) · Jonsson Comprehensive Cancer Center (1) · Kjeld Schmiegelow (1) · Kristoffer Rohrberg (1) · Massachusetts General Hospital (1) · Mylan Pharmaceuticals Inc (1) · National Cancer Institute (NCI) (1) · Nova Laboratories Limited (1) · Tanja Andrea Gruber (1)
United States (13) · Canada (4) · Denmark (3) · Israel (3) · Australia (2) · Norway (2) · South Africa (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Chile (1) · China (1) · Colombia (1)
Yaron Ilan, MD (2) · Brian Shuch (1) · Elias Jabbour, MD (1) · Ibrahim T Aldoss (1) · James D Carlson, Pharm. D. (1) · Kjeld Schmiegelow, Professor (1) · Kristoffer S Rohrberg, MD PhD (1) · Nicholas Short, MD (1) · Philip Amrein, MD (1) · Seth E. Karol, MD (1) · Sima Jeha, MD (1) · Tanja A Gruber, MD, PhD (1)
PMID 41671463, PMID 28859185, PMID 29352703, PMID 35622074, PMID 36215217, PMID 36545256, PMID 37131217, PMID 37187201, PMID 38551807, PMID 41692013, PMID 42234929
2014 (1), P30CA033572 (1), U10CA031946 (1), U10CA098413 (1), U10CA098543 (1), U10CA180886 (1), U10CA180899 (1)